Cost-effectiveness of Umeclidinium/Vilanterol versus aclidinium monotherapy for symptomatic COPD in Colombia: a lifetime Markov Model.
Buendía Jefferson Antonio JA
To evaluate the lifetime cost-effectiveness of once-daily umeclidinium/vilanterol (UMEC/VI) versus twice-daily aclidinium monotherapy for symptomatic chronic obstructive pulmonary disease (COPD) in Colombia. A lifetime Markov model with monthly cycles simulated moderate-to-very-severe COPD in a cohort aged 65 years, incorporating age- and severity-specific background mortality and a 12% case-fatality probability after each severe exacerbation. Comparative efficacy came from a published network meta-analysis; comparator exacerbation probabilities were derived on the rate scale. Costs and quality-adjusted life-years (QALYs) were discounted at 5% annually. Deterministic, scenario, and probabilistic sensitivity analyses were performed. UMEC/VI yielded 8.108 QALYs at US$24,956 per patient versus 6.312 QALYs and US$29,994 for aclidinium (incremental 1.796 QALYs; US$5,038 saved), making UMEC/VI dominant (net monetary benefit US$14,341). UMEC/VI was dominant in 94.7% and cost-effective in 98.6% of probabilistic simulations. Without its exacerbation benefit, UMEC/VI was not cost-effective (net monetary benefit -US$859). UMEC/VI is a high-value COPD maintenance therapy in Colombia, driven by exacerbation reduction rather than drug pricing and conditional on persistence of its clinical benefit.